ESMO - Eur. Oncology· @myESMO · X·· 4 小时前评分70
正文 · 机器翻译
#ESMO26：在内分泌治疗耐药的 #AdvancedBreastCancer 中，下一代 CDK4 抑制剂 atirmociclib 联合 fulvestrant 在 II 期 FOURLIGHT-1 #ClinicalTrial 中将 PFS 延长了 3 个月
🔗 https://ow.ly/99yu5100p14
#InsightsbyESMO #BreastCancer
138 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：ESMO - Eur. Oncology · x.com